Kusajili – Clinical trials directory

Result of your search per sponsor: Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)

Woman and Man Max 99 years
Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF) Update Il y a 4 ans

Effects of F17464 in acute exacerbation of schizophrenia To evaluate the potential efficacy of 40 mg/day of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia

Country None
organs None
Specialty None

Closed trial

More information